Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17049845 | 0.88 | KMT2A (0.65) | ATMKMT2ACA12CA1CA2 | |
| SCHEMBL17513498 | 0.86 | ATM (0.60) | ATML3MBTL1KMT2AKAT6AALDH1A1 | |
| SCHEMBL1348562 | 0.84 | ATM (0.62) | ATML3MBTL1KMT2ACA12CA2 | |
| SCHEMBL6758999 | 0.83 | ATM (0.66) | ATML3MBTL1KMT2AKAT6AALDH1A1 | |
| SCHEMBL30015741 | 0.83 | ATM (0.70) | ATML3MBTL1KMT2AKAT6AALDH1A1 | |
| SCHEMBL5320347 | 0.83 | ATM (0.66) | ATML3MBTL1KMT2AKAT6AALDH1A1 | |
| SCHEMBL1348672 | 0.83 | ATM (0.70) | ATML3MBTL1KMT2AKAT6AALDH1A1 | |
| SCHEMBL1348621 | 0.83 | ATM (0.61) | ATML3MBTL1KMT2AKAT6AALDH1A1 | |
| SCHEMBL29334656 | 0.83 | ATM (0.61) | ATML3MBTL1KMT2AKAT6AALDH1A1 | |
| Hydrochloric Acid SCHEMBL7966569 | 0.83 | ATM (0.61) | ATML3MBTL1KMT2ACA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102203058-B | Sulfur-linked compounds for the treatment of ophthalmic diseases and disorders | ACUCELA INC | 2014-11-12 | — | — | CN | disclosed |
| CN-102203058-A | Sulfur-linked compounds for the treatment of ophthalmic diseases and disorders | ACUCELA INC | 2011-09-28 | — | — | CN | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, MPST, CLN6 | ATM 1621/4885L3MBTL1 1514/4885KMT2A 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.